BlackRock Amends REGENXBIO Stake, Signals Continued Institutional Confidence
Ticker: RGNX · Form: SC 13G/A · Filed: Jan 19, 2024 · CIK: 1590877
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock's still in REGENXBIO, showing big institutional backing.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 19, 2024, indicating a change in its ownership of REGENXBIO Inc. common stock as of December 31, 2023. This filing, Amendment No. 9, shows BlackRock continues to be a significant institutional holder, which can provide a sense of stability for investors. This matters to current or prospective REGENXBIO shareholders because large institutional ownership by a firm like BlackRock often signals confidence in the company's long-term prospects, potentially influencing market perception and stock stability.
Why It Matters
This filing confirms BlackRock's ongoing substantial investment in REGENXBIO, which can be a positive signal for other investors, suggesting institutional belief in the company's future.
Risk Assessment
Risk Level: low — This filing is a routine update from a large institutional investor and does not indicate any immediate negative or highly volatile events for REGENXBIO Inc.
Analyst Insight
An investor should view this as a routine update from a major institutional holder. While it doesn't signal a new buying opportunity or a red flag, it confirms BlackRock's continued presence, which can be a factor in assessing institutional confidence in REGENXBIO. No immediate action is typically warranted based solely on this type of filing, but it's a data point for broader due diligence.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- REGENXBIO Inc. (company) — the subject company whose shares are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 19, 2024 (date) — the date the SC 13G/A was filed
- Amendment No. 9 (number) — the specific amendment number of the filing
FAQ
What type of filing is this document and what does it generally indicate?
This document is an SC 13G/A, which is an amendment to a Schedule 13G. It's filed by institutional investors like BlackRock to report their beneficial ownership of 5% or more of a company's stock, and the 'A' indicates it's an amendment to a previously filed statement, updating their position.
Who is the 'Name of Issuer' in this filing?
The 'Name of Issuer' is REGENXBIO Inc., identified by the CUSIP Number 75901B107 and located at 9804 Medical Center Drive, Rockville, MD 20850.
Who is the 'Reporting Person' in this filing?
The 'Reporting Person' is BlackRock Inc., headquartered at 50 Hudson Yards, New York, NY 10001. They are a large asset manager.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, meaning the reported ownership reflects BlackRock's position as of the end of last year.
Under which rule was this Schedule 13G/A filed?
This Schedule 13G/A was filed under Rule 13d-1(b), which is typically used by institutional investors who acquire shares in the ordinary course of business and not with the purpose or effect of changing or influencing control of the issuer.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 19, 2024 regarding REGENXBIO Inc. (RGNX).